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NMDA receptor antagonism by phencyclidine reduces NWASP and WAVE1
protein expression and reduces levels of myelination markers in the prefrontal
cortex of rats
Abstract
N-methyl-D-aspartate (NMDA) receptor antagonism by perinatal phencyclidine (PCP) treatment leads to
neuronal damage and causes long-term behavioural alterations in rodents. It is routinely used to model
pathological processes in the brain that may be present in schizophrenia, such as alterations to dendritic
development, and disruptions to myelin processes. Both of these processes occur during brain
development and are highly implicated in the schizophrenia pathophysiology. Changes to the
polymerization and reorganization of the actin cytoskeleton can have significant effects on the
morphology and dynamics of the dendrites within the brain. Actin regulation is primarily regulated by
neural Wiskott-Aldrich syndrome protein (NWASP), and WASP-family verprolin homology protein-1
(WAVE1). Here we have examined the role of actin related, cytoskeletal proteins NWASP and WAVE1 in a
neurodevelopmental model of schizophrenia using PCP to determine if these signaling pathways are
altered in the prefrontal cortex and hippocampus throughout different stages of neurodevelopment. Male
Sprague Dawley rats were injected subcutaneously with PCP (10 mg/kg) or saline at postnatal days (PN)
7, 9 and 11. Rats (n=6/group) were sacrificed at PN 12, 5 weeks or 14 weeks. Relative expression levels of
protein expression were examined in the prefrontal cortex and hippocampus of the treated rats. NWASP,
WAVE1 and MBP were decreased (0.001≤p≤0.032) in the prefrontal cortex of PCP treated rats at PN12.
At 5 weeks of age, NWASP was reduced in the prefrontal cortex (p=0.037) and WAVE1 was reduced in the
hippocampus (p=0.006). At 14 weeks, there were no significant changes in any of the tested proteins
(p>0.05). This is the first report of an alteration in NWASP and WAVE1 proteins in the rat brain, directly
following NMDA receptor antagonism by PCP treatment in early development. These findings suggest
that alterations in these important scaffolding related proteins may contribute to the development of
deficits in myelination and cognitive performance in the brain.
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Abstract
N-methyl-D-aspartate (NMDA) receptor antagonism by perinatal
phencyclidine (PCP) treatment leads to neuronal damage and
causes long-term behavioural alterations in rodents. It is routinely used
to model pathological processes in the brain that may be present
in schizophrenia, such as alterations to dendritic development, and
disruptions to myelin processes. Both of these processes occur during
brain development and are highly implicated in the schizophrenia
pathophysiology. Changes to the polymerization and reorganization of
the actin cytoskeleton can have significant effects on the morphology
and dynamics of the dendrites within the brain. Actin regulation
is primarily regulated by neural Wiskott-Aldrich syndrome protein
(NWASP), and WASP-family verprolin homology protein-1 (WAVE1).
Here we have examined the role of actin related, cytoskeletal proteins
NWASP and WAVE1 in a neurodevelopmental model of schizophrenia
using PCP to determine if these signaling pathways are altered in
the prefrontal cortex and hippocampus throughout different stages
of neurodevelopment. Male Sprague Dawley rats were injected
subcutaneously with PCP (10 mg/kg) or saline at postnatal days (PN)
7, 9 and 11. Rats (n=6/group) were sacrificed at PN 12, 5 weeks or 14
weeks. Relative expression levels of protein expression were examined
in the prefrontal cortex and hippocampus of the treated rats. NWASP,
WAVE1 and MBP were decreased (0.001≤p≤0.032) in the prefrontal
cortex of PCP treated rats at PN12. At 5 weeks of age, NWASP was
reduced in the prefrontal cortex (p=0.037) and WAVE1 was reduced
in the hippocampus (p=0.006). At 14 weeks, there were no significant
changes in any of the tested proteins (p>0.05). This is the first report of
an alteration in NWASP and WAVE1 proteins in the rat brain, directly
following NMDA receptor antagonism by PCP treatment in early
development. These findings suggest that alterations in these important
scaffolding related proteins may contribute to the development of
deficits in myelination and cognitive performance in the brain.

Introduction
Glutamate is the primary excitatory neurotransmitter in the brain
and through its actions predominantly on NMDA receptors, plays a
key role in neurodevelopmental processes such as neuronal migration,
synaptogenesis and synaptic plasticity in both cortical and sub cortical
regions [1]. Phencyclidine or 1-(1-phenylcyclohexyl) piperidine
(also known as PCP) is a potent non-competitive NMDA receptor
antagonist [2-4]. To a lesser extent, PCP also has a lower binding
affinity for several other targets including dopaminergic D2, nicotinic
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and muscarinic cholinergic receptors, as well as μ, κ and σ classes of
opiate receptors [5-8]. In healthy human subjects, administration
of PCP induces hallucinations and delusions which are common
symptoms of schizophrenia; furthermore the administration of PCP
to schizophrenia patients exacerbates their positive symptoms [9],
thus a number of pharmacological models of schizophrenia have been
developed using the administration of PCP to rodents (for review see
[9]). Since the effects of PCP treatment in rodents are translatable
to humans and other higher order primates, the administration
of PCP is now one of the best known pharmacological models of
schizophrenia [10,11]. Administering perinatal PCP to postnatal
rodents has both the construct validity and face validity to test and
address the proposed neurodevelopmental origins of schizophrenia.
The administration of PCP at postnatal day (PN) 7, 9 and 11, which
broadly corresponds to the second trimester of pregnancy in humans
[12], has consistently been shown to induce hyperlocomotion, reduce
prepulse inhibition and impair social interactions in rodents in
adulthood [13-15], as previously published by our research group. All
these behaviors illustrate symptoms encountered in schizophrenia
pathology [9]. Due to its effects on a multitude of important
receptor targets known to be involved in the pathophysiology of
schizophrenia, and the schizophrenia-like behaviors, and symptoms
it induces in rodents and humans respectively, PCP administration in
rodents is now one of the most commonly used models for studying
the development of schizophrenia [3,16,17]. In the postnatal period,
from about PN7 to 14, neurons are highly sensitive to the toxic
effects of NMDA receptor antagonists [18]; however neurons are
not the only brain cells that are affected by disruptions to NMDA
receptor antagonists. Oligodendrocytes are also very sensitive to PCP
toxicity during development [19], and since they play a significant
role in axonal connectivity and conduction, disruption to these
processes during the early stages of brain development could impact
significantly on normal brain development in its later stages.
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In addition to oligodendrocytes playing a significant role in nerve
conductivity and communication, postsynaptic dendritic spines
are also largely responsible for information processing and storage
in neurons, as well as synaptic plasticity [20], all of which critically
underlie learning and memory processes. Within the dendrites, it is
the configuration of the actin cytoskeleton that is largely responsible
for the regulation of synaptic spine formation and morphology;
thus changes to the polymerization and reorganization of the actin
cytoskeleton can have a significant impact on the morphology
and dynamics of dendritic spines, which could lead to cognitive
dysfunction [21].
Polymerization, reorganization and branching of the actin
cytoskeleton are primarily regulated by the actin-related proteins
(Arp2/3) complex. The binding of the Arp2/3 complex to the side
of an existing actin filament elicits the polymerization of actin,
resulting in filament branching [22]. The Arp2/3 complex is primarily
regulated by neural Wiskott-Aldrich syndrome protein (NWASP),
and WASP-family verprolin homology protein-1 (WAVE1)
[23]. Loss of hippocampal NWASP and Arp3 has been shown to
significantly reduce both the number of dendritic spines and the
number of excitatory synapses [24]. Furthermore, genetic knockout
of WAVE1 leads to hippocampal and cortical dysfunction, through
a reduction in spine density and alterations in synaptic transmission
[25]. WAVE1 knockout mice demonstrate learning and memory
deficits, and display reduced sensorimotor function [26].
Since neuronal changes in NWASP and WAVE1 expression
have been shown to induce alterations in dendritic spine growth
and synaptic transmission [24,25,27], which both underlie learning
and memory processes; we examined the levels of expression of
these proteins throughout development in the prefrontal cortex and
hippocampus of rats following perinatal administration of the potent
NMDA receptor antagonist PCP. Furthermore, we also examined
levels of myelination related proteins myelin basic protein (MBP)
and myelin oligodendrocyte glycoprotein (MOG), since NWASP and
WAVE1 are also critically involved in oligodendrocyte differentiation
and myelination [28,29] which are also implicated in cognition.

Materials and Methods
Animals
Timed pregnant Sprague Dawley rats were obtained at gestation
day 14 from the Animal Resource Centre (Perth, WA, Australia).
They were housed in environmentally controlled conditions at 22 °C
in a 12:12 hour light dark cycle with free access to food and water. The
day of birth was considered PN0. Pups were sexed on PN7 and were
randomly assigned to PCP or saline groups. The female pups were
kept in the litters, however only male rats were used in this study.
Pups were weaned at PN24-28, and were housed in pairs according to
treatment. This study was approved by the Animal Ethics Committee
at the University of Wollongong (AE13/01), and was conducted
according to the guidelines of the Australian code of Practice for the
Care and Use of Animals for Scientific Purposes, conforming to the
International Guiding Principles for Biomedical Research Involving
Animals. All efforts were made to minimize numbers of animals used
and their suffering.
J Pharmaceu Pharmacol 3(1): 8 (2015)

Perinatal PCP treatment
Male Sprague Dawley rat pups were given a subcutaneous
injection on PN7, 9 and 11; of PCP (10 mg/kg/day; Sigma, Castle Hill,
NSW, Australia) or saline (0.9% NaCl at a volume of 1 ml/kg), as our
group and others have previously shown that this treatment regime
produces PCP induced alterations in sensorimotor gating, locomotor
activity and working memory in rats [13,14,30,31]. Additionally, the
acute effects of PCP administration were validated by observing an
immediate increase in locomotor activity in the PCP treated pups
compared to saline treated pups. Six rats from each group (PCP and
control) were sacrificed at three different time points, PN12 days, 5
weeks or 14 weeks of age as described previously [18,32]. These timepoints represent perinatal, adolescent and adult developmental stages
respectively, and were chosen because they are relevant and distinct
brain developmental periods [33].

Rat brain tissue preparation
Rats were sacrificed by carbon dioxide asphyxiation and
decapitation at PN12, 5 weeks and 14 weeks. Brains were rapidly
removed and the prefrontal cortex and hippocampus was regionally
dissected on ice with the aid of a standard rat brain atlas [34]. Samples
were snap frozen in liquid nitrogen and then stored at -80 °C. Tissue
was homogenized gently in a homogenizing buffer (50 mM Tris pH
7.5, 50 % glycerol), containing a protease inhibitor cocktail (Sigma).
Protein concentrations were determined by a spectrophotometer. All
samples were diluted to a concentration of 2 μg/μL and stored at -80
°C until required for immunoblotting, as previously detailed [35].

Immunoblotting
Relative levels of all proteins were determined by immunoblot
analysis as previously described [35]. In short, proteins were resolved
by SDS-PAGE with a total of 10 µg protein loaded into each well of
the gel. Separated proteins were then transferred to polyvinylidene
fluoride membranes (Bio-Rad). Membranes were probed with antiNWASP (1:1000; ab23394 Abcam), anti-WAVE1 (1:2500; ab50356
Abcam), anti-MBP (1:1000; ab53294 Abcam), and anti-MOG
(1:10000; MAB5680 Millipore) primary polyclonal or monoclonal
antibodies. Visualization and quantification of immunoblot bands
was performed using the Gel Logic 2200 Pro (Carestream Molecular
Imaging; Rochester, NY, USA). Samples were loaded in a randomized
order with even numbers of PCP and control samples per time point
per gel to minimize the effects of gel-to-gel variability on the results.
A pooled sample combining aliquots from all 36 rats, was used as a
positive control and was loaded onto each gel within the experiment
to account for any gel-to-gel variability. Samples from each gel
were then normalized to their respective pooled sample, and all
immunoblot bands were normalized to a β-actin (1:5000; MAB1501
Millipore) same lane loading control. Mean β-actin expression
levels did not differ between PCP and control groups (p>0.05). All
experiments and quantifications were performed blind to treatment
and age group.

Statistics
Statistical analyses were performed using SPSS (version 20.0,
SPSS Inc. Chicago, USA). Protein analyses were performed on 5-6
biological replicates per treatment per time-point, with experiments
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performed in 2-3 technical replicates. As all data were normally
distributed (K-S p>0.10), parametric testing was implemented.
Differences between treatment and control groups were analyzed
at individual time-points using unpaired two-tailed t-tests. The
significance for all statistical tests was set to p<0.05.

Results
Prefrontal cortex
PN12: Relative levels of NWASP expression were found to be
significantly decreased by 23.5% in the prefrontal cortex of perinatal
PCP treated rats at PN12 (t1,7=2.665; p=0.032; Figure 1). Similarly,
WAVE1 expression levels were also found to be significantly decreased
by 17.5% in PCP treated rats compared to control rats at PN12

(t1,7=6.117; p<0.001; Figure 1). Furthermore, there was a significant
17.5% decrease in the protein expression of the myelination marker
MBP in rats treated with PCP compared to control rats at PN12
(t1,7=3.266; p=0.013; Figure 1); however there were no significant
alterations in expression levels of the MOG marker of myelination (t
=1.345; p=0.208) in the PN12 PCP treated rats compared to control
1,10
rats (Figure 1).
5 weeks: Interestingly, NWASP was the only protein to show
significant alterations in expression levels in the prefrontal cortex
of the adolescent 5 week old rats; and it was only a minor change
with an 8% decrease in NWASP expression in the PCP treated rats at
adolescence (t1,10=2.405; p=0.037; Figure 1). There were no significant
alterations in the expression levels of WAVE 1(t1,10=0.4676; p=0.650),
or in either of the myelination markers MBP (t1,8=0.5707; p=0.5838)

Figure 1: Levels of protein expression in the prefrontal cortex of phencyclidine (PCP) treated rats (black bars) compared to controls (white bars).* p<0.05 and ***
p<0.001.

J Pharmaceu Pharmacol 3(1): 8 (2015)
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or MOG (t1,10=0.6339; p=0.540) in the 5 week PCP treated rats
compared to control rats (Figure 1).
14 weeks: Perinatal PCP treatment resulted in no significant
alterations in cortical levels of NWASP protein at 14 weeks during
adulthood (t1,10=0.5414; p=0.601; Figure 1). Additionally there
were no significant differences in WAVE1 expression in the PCP
treated rats compared to controls (t1,10=0.1405; p=0.891; Figure 1).
Furthermore, levels of expression of both of the tested myelination
markers MBP (t1,9=0.1987; p=0.847) and MOG (t1,9=0.2912; p=0.777)
were unaltered in the 14 week perinatal PCP treated rats compared to
controls (Figure 1).

Hippocampus
PN12: There was a very large 42% decrease in hippocampal
WAVE1 protein expression in juvenile PCP treated rats compared to

control rats (t1,10=3.659; p=0.004; Figure 2). In contrast, relative protein
expression levels of NWASP (t1,10=1.456; p=0.176), and myelination
markers MBP (t1,8=1.509; p=0.169) and MOG (t1,10=0.0447; p=0.965)
were not significantly altered in the hippocampus of juvenile PCP
treated rats (Figure 2).
5 weeks: Similarly, during adolescence, WAVE1 was the only
protein to be significantly altered, with a decrease of 16% in PCP
treated rats compared to controls (t1,10=3.428; p=0.006; Figure 2);
whereas levels of NWASP (t1,10=0.0444; p=0.965), MBP (t1,9=1.067;
p=0.314) and MOG (t1,10=0.1822; p=0.859) remained unaltered in the
hippocampus of the adolescent treated rats (Figure 2).
14 weeks: Perinatal PCP treatment resulted in no significant
alterations in hippocampal levels of NWASP protein during
adulthood (t1,10=1.385; p=0.1962; Figure 2). Additionally there were

Figure 2: Levels of protein expression in the hippocampus of phencyclidine (PCP) treated rats (black bars) compared to controls (white bars). ** p<0.01.
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no significant differences in adult levels of hippocampal WAVE1
expression in the PCP treated rats compared to controls (t1,10=0.8784;
p=0.401; Figure 2). Furthermore, levels of expression of both of the
tested myelination markers MBP (t1,7=0.2870; p=0.7824) and MOG
(t1,9=0.7322; p=0.4827) were unaltered in the 14 week perinatal PCP
treated rats compared to controls (Figure 2).

Discussion
This is the first study to examine the developmental expression
profile of the scaffolding proteins NWASP and WAVE1, in addition
to myelin related proteins MBP and MOG in a neurodevelopmental
PCP model of schizophrenia. This study offers insight into the role of
these proteins following administration of a potent NMDA receptor
antagonist during a critical neurodevelopmental period, which is
also pertinent to the development of schizophrenia. In the present
study, cortical levels of protein expression of NWASP, WAVE1 and
MBP were significantly reduced in the juvenile PCP treated rats, and
cortical levels of NWASP were slightly reduced in the adolescent PCP
treated rats. In the hippocampus, WAVE1 was the only protein to
have its expression levels altered, with a significant decrease observed
in both PN12 and 5 week old PCP treated rats compared to their
controls. Considering the current literature and the role that these
scaffolding and myelin related proteins play in synaptic plasticity
and myelin related processes, our results suggest that not only are
NWASP and WAVE1 sensitive to the effects of NMDA receptor
antagonism by PCP, but that they may contribute to the development
of myelination deficits in the brain.

NMDA receptor antagonism by PCP acutely reduces
expression of NWASP, WAVE1 and MBP proteins in the
prefrontal cortex of juvenile rats
Impaired glutamate signaling results in significant alterations
in synapse number and synaptic communication, and has been
correlated with neuronal, cognitive and behavioral dysfunction in
a wide range of neuropsychiatric disorders including schizophrenia
[36]. Similarly, PCP administration in rats has been shown to
significantly reduce the number of dendritic spine synapses in the
prefrontal cortex, for up to 4 weeks following the cessation of PCP
treatment [37,38], and induce significant cognitive impairment
in both monkeys [39] and rats [40-43]. NWASP and WAVE1 are
important regulatory proteins involved in maintaining the actin
cytoskeleton [22] and are critical for the development of dendritic
spines and synapses [24,25].We have shown NWASP and WAVE1
protein expression to be significantly reduced in the prefrontal cortex
of juvenile PCP treated rats compared to controls. Since neuronal
changes in NWASP and WAVE1 expression have been shown to result
in alterations in dendritic spine growth and synaptic transmission
[24,25,27], it was not surprising to find significant reductions of
both of these proteins in the prefrontal cortex of PCP treated rats.
Significant deficits in NWASP and WAVE1 protein expression have
previously been observed in NMDA receptor knock-down mice, with
the reduced levels of the NMDA receptor having a more profound
effect of on WAVE1 expression [44].
The integrity of myelin is crucial to the functionality of
neurocircuitry, and disruption to myelin during development, or
even after its formation can have severe neurological consequences
J Pharmaceu Pharmacol 3(1): 8 (2015)

[45]. Oligodendrocytes are known to express several regulatory actinbinding proteins including NWASP [28], and NWASP knockout
PN10 neuronal cultures have been shown to have severely reduced
levels of myelin related gene expression, whereby only trace amounts
of MBP were detectable in the NWASP mutant cells compared to
controls [46]. Moreover, WAVE1 knockout mice show defective
morphogenesis of oligodendrocytes and regional hypo-myelination
[29]. In addition, both NWASP and WAVE1 protein expression
levels are increased at PN15, the time of onset of MBP expression
in rat brain lysates [47]. To date only two studies have shown
myelination deficits in rodents following PCP administration. One
study administered PCP to the rats in utero [48], and the other to
postnatal rat pups [49]. Both studies reported significant deficits in
levels of myelination, as measured by MBP expression, in the cortex
of rats exposed to PCP compared to controls [48,49]. In light of the
current literature, we hypothesize that the deficits in MBP levels that
we have observed in the prefrontal cortex of juvenile PCP treated rats
may be caused by the significant downregulation of NWASP and
WAVE1 proteins in the treated rats.
Myelination processes in the hippocampus occur during the
embryonic period which is a pivotal period for the development
of schizophrenia [50], while myelination of the neurons within the
dorsolateral prefrontal cortex occurs in late adolescence, which
correlates with the age of onset of schizophrenia [51]. Despite MBP
and MOG levels being unaltered in the hippocampus of PCP treated
rats compared to control rats in all of the tested age groups, MBP
levels as a marker of mature oligodendrocytes and myelination
were significantly greater in the hippocampus than in the prefrontal
cortex of the juvenile control rats (p=0.002) whereas they were
not significantly different in PCP treated rats (p=0.141) (Figure 3).
Furthermore although not reaching statistical significance, MBP
levels were elevated in the prefrontal cortex of PCP treated compared
to control rats at adolescence. These juvenile and adolescent MBP
levels seen in our study are in accordance with what would be expected
to occur in normal brain development, with the hippocampus being
more highly myelinated during early development, and the prefrontal
cortex being slow to begin with, but taking over at adolescence [50].
It is interesting that we reported differential expression patterns
of myelin related protein expression across the prefrontal cortex
and hippocampus following perinatal PCP treatment in this study;
however it is not uncommon to observe variations in expression
patterns within different regions of the brain due to the regional
differences in heterogeneity in cyto- and chemo-architecture. We
suspect that the perinatal PCP treatment may have affected the
developmental trajectories of these myelin related proteins to varying
degrees early on in development.

Hippocampal levels of WAVE1 but not NWASP or myelin
related proteins MBP and MOG are altered by perinatal
PCP administration
Hippocampal expression levels of WAVE1 were found to be
significantly decreased in PCP treated rats compared to control rats
at both juvenile and adolescent time-points, whereas hippocampal
levels of NWASP were not found to be significantly altered by PCP
treatment. In support of this, expression levels of WAVE1 have been
shown to be more susceptible to the effects of NMDA receptor knockPage - 05
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Even though the change in NWASP was very minimal across
development, both NWASP and WAVE1 proteins were increased
during adolescence (Figure 2). Due to the extensive synaptic changes
that occur during adolescence (reductions in dendritic arborization,
and pruning of synapses) [53], it was not surprising to observe higher
levels of these important regulators of the actin cytoskeleton at this
critical period of development in the control rats.
Cognitive deficits observed in patients with schizophrenia are
particularly attributable to prefrontal cortex and hippocampal
dysfunction, and since a large number of studies have consistently
found that the largest changes in the expression of oligodendrocytes
and myelin-related genes in schizophrenia are in the prefrontal
cortex, cingulate cortex, hippocampus and superior temporal gyrus
[54-59], it seems plausible to suggest that the cognitive dysfunction
seen in schizophrenia is related to the alterations in myelin-related
genes in these regions. As briefly mentioned above, while we did
not observe hippocampal levels of myelin related proteins to be
significantly altered in PCP treated rats compared to controls, we did
notice that hippocampal levels of these proteins were not significantly
different from those observed in the prefrontal cortex of PCP treated
rats, whereas in control rats these levels were significantly different
at PN12 (Figure 3). We hypothesize that the lack of a statistically
significant difference in the hippocampus compared to the prefrontal
cortex levels of myelin related proteins in PCP treated rats, may be
playing a role in some of the PCP induced cognitive deficits that are
observed in rodent models of schizophrenia, long-term abusers of PCP
[38], and in schizophrenia patients [45]. In support of this, injections
of potent demyelination agents into the ventral hippocampus of 10
day old rat pups has been shown to induce a variety of schizophrenia
related endophenotypes, including deficits in prepulse inhibition,
hyper locomotion and inducing anxiety related behaviors, suggesting
that demyelination plays an important role in the development and
severity of schizophrenia [60].
Figure 3: Levels of protein expression of myelin basic protein (MBP) as
a marker of myelination in the prefrontal cortex (white bars) compared to
hippocampus (grey bars) across normal brain development (in control rats)
and following phencyclidine (PCP) administration. ** p<0.01.

down than those of NWASP [44], and WAVE1 expression is not
detectable in the hippocampus of WAVE1 knockout mice [26].
WAVE1 expression has been shown to be specific to the brain
in mice, with the highest expression levels being detectable in the
striatum, cortex and hippocampus [26]. Genetic knockout of WAVE1
results in significant reductions in hippocampal and cortical dendritic
spine densities, and alterations in synaptic plasticity [25] along with
deficits in learning and memory [26]. In line with the literature,
we hypothesize that the significant reduction in WAVE1 protein
expression observed in our PCP treated rats, may be at least partly
responsible for the synaptic and behavioural deficits observed in
schizophrenia animal models involving NMDA receptor antagonism.
In further support of our hypothesis, both NMDA receptor knockdown mice and PCP treated rats, in addition to WAVE1 knockout
mice show similar alterations in their behavior and synaptic
morphology [25,26,37,44,52].
J Pharmaceu Pharmacol 3(1): 8 (2015)

Summary and Conclusion
Here we provide the first report of alterations in the actin related
cytoskeletal proteins NWASP and WAVE1, in the prefrontal cortex
and hippocampus of rats from a neurodevelopmental PCP model of
schizophrenia. We have shown an altered developmental trajectory of
these signaling proteins following PCP administration, in particular
at the perinatal stage of life. The results of this study in concert with
the current literature, suggest that NWASP and especially WAVE1
are sensitive to the effects of NMDA receptor antagonism by PCP
administration, and that alterations in these scaffolding related
proteins may contribute to the development of myelination deficits
in the brain, and more broadly, deficits in cognitive performance.
Further studies will be required to fully elucidate the molecular
mechanisms involved.
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